The page you requested is a research briefing from Medical Xpress that summarizes a study on how a biomarker can track the recovery from treatment-resistant depression using deep brain stimulation (DBS). Here is a brief summary of the page:
- The study, published in Nature, involved 10 patients with severe treatment-resistant depression who underwent DBS, a therapy that involves implanting electrodes in the brain to deliver electrical pulses1.
- The researchers used a new DBS device that allowed them to record the brain activity of the patients over six months. They used artificial intelligence to analyze the brain recordings and identify a common pattern in brain activity that changed as each patient recovered from their depression1.
- This pattern, known as a biomarker, serves as a measurable indicator of disease recovery and represents a significant advance in treatment for the most severe and untreatable forms of depression. The biomarker can help clinicians monitor the patient’s response to DBS therapy and adjust it accordingly to optimize the treatment outcomes1.
- The study also offers the first insight into how DBS affects the brain during treatment for depression. The researchers found that DBS increased the activity of brain regions involved in emotion regulation and reduced the activity of brain regions involved in negative emotions1.